Spherix Inc  

(Public, NASDAQ:SPEX)   Watch this stock  
Find more results for SPEX
6.95
-0.06 (-0.86%)
May 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 6.95 - 7.10
52 week 5.51 - 16.20
Open 7.10
Vol / Avg. 2,027.00/2,814.00
Mkt cap 5.66M
P/E     -
Div/yield     -
EPS -10.81
Shares 813,714.00
Beta 0.21
Inst. own 13%
May 13, 2013
Q1 2013 Spherix Inc. Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '12) 2012
Net profit margin -39405.92% -14498.14%
Operating margin -34440.19% -17429.77%
EBITD margin - -17108.48%
Return on average assets -116.79% -55.48%
Return on average equity -281.60% -124.15%
Employees 3 -
Carbon Disclosure Rating - -

Address

Suite 3125, 7927 Jones Branch Drive
TYSONS CORNER, VA 2102
United States - Map
+1-301-8972565 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Discussion Group - Google Finance

Description

Spherix Incorporated (Spherix) is a scientific research company. The Company is enaged in developing biopharmaceutical products and providing technical and regulatory consulting services to food, consumer products and pharmaceutical companies. The Company operates in two segments: Biospherics Incorporated (Biospherics), the Company's biotechnology research and development business, and Health Sciences, a technical and regulatory consulting business. The Company has created two wholly owned subsidiaries, Biospherics Incorporated and Spherix Consulting, Inc. (Spherix Consulting), for its two operating segments. The Company's Health Sciences contracts are in the name of Spherix Consulting, and the Company's patents are in the name of Biospherics Incorporated. Spherix provides management, strategic guidance, business development, marketing and other services to its subsidiaries.

Officers and directors

Robert J. Vander Zanden Ph.D. Independent Chairman of the Board
Age: 66
Bio & Compensation  - Reuters
Robert A. Lodder Jr., Ph.D. President
Bio & Compensation  - Reuters
Harvey J. Kesner Interim Chief Executive Officer, Director
Age: 55
Bio & Compensation  - Reuters
Robert L. Clayton Chief Financial Officer, Treasurer, Secretary
Age: 49
Bio & Compensation  - Reuters
Edward M. Karr Director
Bio & Compensation  - Reuters
Douglas T. Brown Independent Director
Age: 58
Bio & Compensation  - Reuters